T5O0 — bioXXmed AG Income Statement
0.000.00%
Last trade - 00:00- €1.07m
- €0.98m
- €0.02m
Annual income statement for bioXXmed AG, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | — | — | — | GAS | GAS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.036 | 0.036 | 0.045 | 0.012 | 0.017 |
| Cost of Revenue | |||||
| Gross Profit | 0.036 | — | — | — | — |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 1.21 | 1.87 | 1.57 | 0.835 | 0.864 |
| Operating Profit | -1.17 | -1.84 | -1.53 | -0.823 | -0.846 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -1.27 | -1.84 | -4.02 | -0.83 | -21 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -1.27 | -1.84 | -4.06 | -0.83 | -20.9 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -1.27 | -1.84 | -4.06 | -0.83 | -20.9 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -1.27 | -1.84 | -4.06 | -0.83 | -20.9 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -2.77 | -3.64 | -8.02 | -1.32 | -33.4 |
| Dividends per Share |